Induct AS (OSL:INDCT)
Norway
· Delayed Price · Currency is NOK 3.760
-0.040 (-1.05%)
At close: Aug 15, 2025
Induct AS Revenue
Induct AS had revenue of 4.89M NOK in the quarter ending June 30, 2025, with 9.98% growth. This brings the company's revenue in the last twelve months to 17.24M, down -18.79% year-over-year. In the year 2024, Induct AS had annual revenue of 17.96M, down -14.62%.
Revenue (ttm)
17.24M
Revenue Growth
-18.79%
P/S Ratio
6.83
Revenue / Employee
1.33M
Employees
13
Market Cap
117.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17.96M | -3.08M | -14.62% |
| Dec 31, 2023 | 21.04M | 1.60M | 8.25% |
| Dec 31, 2022 | 19.44M | 5.13M | 35.85% |
| Dec 31, 2021 | 14.31M | 2.70M | 23.32% |
| Dec 31, 2020 | 11.60M | -2.18M | -15.84% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medistim ASA | 603.92M |
| Nordhealth AS | 545.88M |
| Photocure ASA | 522.86M |
| ArcticZymes Technologies ASA | 104.33M |
| Vistin Pharma ASA | 440.66M |
| Omda AS | 442.14M |
| Gentian Diagnostics ASA | 163.38M |
| Lytix Biopharma AS | 608.00K |